Life Sciences Tools and Services
Company Overview of Second Genome, Inc.
Second Genome, Inc., a life sciences company, develops microbiome-modulating precision therapies. Its microbiome signature discovery services include solutions for microbiome analysis, such as biological specimen storage and sample preparation; sequencing (NGS) and array-based metagenomic assays; and bioinformatics pipelines. Second Genome, Inc. was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in San Bruno, California.
1150 Bayhill Drive
San Bruno, CA 94066
Founded in 2009
Key Executives for Second Genome, Inc.
Chief Executive Officer and President
Co-Founder and Chairman of the Board
Co-Founder and Chairperson of Scientific Advisory Board
Co-Founder and Head of Bioinformatics
Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2014.
Second Genome, Inc. Key Developments
Second Genome Enters into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
May 2 14
Second Genome announced that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders. The worldwide prevalence of obesity and associated metabolic conditions continues to increase rapidly. Emerging evidence suggests that the microbiome is central to metabolic processes. Changes in the composition of gut microbes appear to be linked to metabolic conditions such as obesity and type 2 diabetes. Recent microbiome transplant studies have demonstrated that the introduction of specific microbes can influence host biology to drive weight loss or gain, suggesting the microbiome may be a therapeutic target for obesity treatments.
Second Genome Announces Board Appointments
Jun 5 13
Second Genome, Inc. announced the appointment of Brad A. Margus, former CEO and co-founder of Envoy Therapeutics, to its board of directors; and Jerrold M. Olefsky, Professor of Medicine at the University of California, San Diego to its scientific advisory board.
Second Genome, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-09-2013 11:45 AM
Nov 29 12
Second Genome, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-09-2013 11:45 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries